Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (March 2023)

41 slides from Marinus Pharmaceuticals's investor presentation, Mar 7, 2023

  1. Slide 1: Corporate Presentation March 2023

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation March 2023

  2. Slide 2: Forward-looking statements

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 PDUFA date March 2022 MAA filing validation Q4 2021 Ph3 patient enrollment Q1 2022 Topline data 1H 2024 GANAXOLONE Phase 1 Phase 2 Phase 3 Approved Oral Suspension Intravenous Intravenous Intravenous Oral Suspensi

  4. Slide 4: Ganaxolone U.S. Market Opportunity

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 4 ¹Symonds JD 2019 Brain ²Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–68. ³DeLorenzo RJ et al. J Clin Neurophysiol. 1995; 12: 316-325 4Kapur et al. N Engl J Med 2019;381:2103-13 5Rossetti and Lowenstein. Lancet N

  5. Slide 5: ZTALMY Marigold Clinical Data & Commercial Launch

    ZTALMY® (ganaxolone) oral suspension CV Marigold Clinical Data & Commercial Launch Not for promotional use

  6. Slide 6: Marigold seizure frequency reduction

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 6 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction in

  7. Slide 7: ZTALMY Performance Metrics Indicate Early Launch Success

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics Indicate Early Launch Success 7 • $2.3M ZTALMY® U.S. net product revenues • ~40 completed CDD prescription enrollment forms received from 30+ unique accounts • ~90 completed CDD prescription enrollment forms received fr

  8. Slide 8: ZTALMY U.S. Market Opportunity & Key Accounts

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY U.S. Market Opportunity & Key Accounts 8 ~2,000 Addressable Pediatric Patients* Several data points suggest additional market opportunity in adult population 1Symonds JD 2019 Brain *Estimated based on Symonds JD 2019 Brain • 8 CDD Centers o

  9. Slide 9: Rare Epilepsies Oral Ganaxolone Pipeline

    Rare Epilepsies Oral Ganaxolone Pipeline

  10. Slide 10: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  11. Slide 11: Tuberous Sclerosis Complex (TSC)

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 11 Tuberous Sclerosis Complex (TSC) 1 diMichele, et al, J. Neuro Neurosurg Psychiatry, 2003 *Failure of two prior antiseizure medications with ongoing, frequent seizures. CAUSE • Defect or mutation of TSC1 and/or TSC2 genes SYMPTOMS • Benign tumor

  12. Slide 12: TSC Phase 2 Trial Results

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 12 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  13. Slide 13: Phase 3 Protocol Refinements Informed by Phase 2

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 13 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy 0 7 14 21 28 35 0 20 40 60 80 100 Time (days) Approx. % Max GNX Dose TSC Ph2 Titration TSC Ph3 Titration

  14. Slide 14: Phase 3 Trial Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 14 ► Enrollment: ~162 patients, targeting 85 sites in the U.S., Western Europe, Canada, Israel and Australia ► Primary Endpoint: Percent change in 28-day TSC-associated seizure frequency ► Key Secondary Endpoints: Percent ch

  15. Slide 15: Second Generation Product Development

    Second Generation Product Development

  16. Slide 16: Second Generation Ganaxolone Goals

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 16 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce dosing fr

  17. Slide 17: Oral Reformulation Single Ascending Dose PK

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Oral Reformulation Single Ascending Dose (SAD) PK Ganaxolone reformulation demonstrates linear kinetics at single doses from 100-1200 mg 0 500 1000 1500 2000 2500 3000 3500 100 200 300 400 500 600 700 800 900 1000 1100 1200 Mean AUC0-t (ng

  18. Slide 18: Modeling of multiple dose BID PK from SAD data

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 18 Modeling of multiple dose BID PK from SAD data Cmax ~ 187 ng/mL Cmin~ 50 ng/mL Steady state PK modeling shows linear dose exposure relationship up to 1500 mg BID for ganaxolone reformulation 0.0 50.0 100.0 150.0 200.0 250.0 300.0 350.0 400.0 45

  19. Slide 19: Next Steps: Ganaxolone Reformulation and Prodrug

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Ganaxolone Reformulation and Prodrug 19 Ganaxolone Prodrug Cohort Dose (BID) N Vehicle Diet 1 600 6 A A 2a 900 6 B B 2b 900 6 B A 2c 900 6 C A 3a 1200 6 B B 3b 1200 6 B A MAD Trial design • Healthy adult volunteers • 36 subjects in 6 e

  20. Slide 20: Development plan goals

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Development plan goals • Efficiently select next generation product for clinical development in LGS and other potential indications • Proceed with targeted investments in parallel formulation and prodrug development to accelerate entry to Phase 2/

  21. Slide 21: Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

  22. Slide 22: Status Epilepticus

    Status Epilepticus

  23. Slide 23: Status Epilepticus (SE): Definition and Epidemiology

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus (SE): Definition and Epidemiology 23 SE is the second most common neurologic emergency in the U.S.1 150,000 cases per year2 1. Anesthesia and Intensive Care Medicine, February 02, 2018 , Update on the management of status epilep

  24. Slide 24: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 24 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  25. Slide 25: Strategic Approach to SE Clinical Development

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 25 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Stat

  26. Slide 26: Refractory Status Epilepticus Trial Design

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 26 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non-convulsive SE • Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Bolu

  27. Slide 27: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 27 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through

  28. Slide 28: PK/PD Relationship and Rationale for Target Dose

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I 28 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieved Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  29. Slide 29: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RAISE: Phase 3 Trial in Refractory Status Epilepticus 29 Ganaxolone development for RSE is being funded, in part, by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness

  30. Slide 30: Patient Demographics: RSE Phase 2 vs. Phase 3

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Patient Demographics: RSE Phase 2 vs. Phase 3 30 *This is preliminary data is as of the end of Q3 2022 and may not be representative of demographics of patients upon full enrollment of the RAISE trial Age (mean range) Consented Subjects Dosed Hist

  31. Slide 31: RESET: Phase 2 Trial in Established Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RESET: Phase 2 Trial in Established Status Epilepticus 31 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Key Trial points: • Patients with convulsive status epilepticus • N

  32. Slide 32: RESET Trial Design in Established Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RESET Trial Design in Established Status Epilepticus 32 Screening <30 min Enrollment Fail BZD IV ganaxolone infusion 1 IV ganaxolone infusion 3 SOC IV AED Convulsive SE (N=40) Ganaxolone bolus Ganaxolone bolus Ganaxolone bolus Seizures YES NO Seiz

  33. Slide 33: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 33 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV Anes

  34. Slide 34: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  35. Slide 35: Clinical and Healthcare Costs Associated with RSE

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 35 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  36. Slide 36: Differentiated Market Access Strategy for IV Ganaxolone

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Differentiated Market Access Strategy to Ensure Success for IV Ganaxolone Formulation (DRG), diagnosis-related group reimbursement 36 PRICING & REIMBURSEMENT • U.S./EU Pricing research initiated and ongoing • Determining New Technology Add-on Paym

  37. Slide 37: Financial Update

    Financial Update

  38. Slide 38: Financial Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 38 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgins Op

  39. Slide 39: Liquidity Overview

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Liquidity Overview 39 Note: All values shown are gross transactional proceeds 1 Marinus potential to draw subject to achievement of certain clinical and financial milestones Financial Summary (as of December 31, 2022): • $240.6 million in cash and

  40. Slide 40: Intellectual Property

    Intellectual Property

  41. Slide 41: Multiple Layers Of Potential Protection

    ©2023 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 41 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. Paten

Marinus Pharmaceuticals — Investor Presentation (March 2023) on 6ix